Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 3

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 3
---
 common stock that would be issuable upon a cash rather than a cashless exercise of the Series B Warrant and (ii) 3.0. Accordingly, it is highly unlikely that a holder of the Series B Warrants would wish to pay an exercise price in cash to receive one share of common stock when they could instead choose the alternative cashless exercise option and pay no cash to receive three shares of common stock. As a result, we will likely not receive any additional funds and do not expect to receive any additional funds upon the exercise of the Series B Warrants. In the event that we are unable to obtain the Warrant Stockholder Approval, the Series Warrants will not be exercisable and therefore may have no value. See the Risk Factor on page 12 relating to the Series A Warrants and Series B Warrants and Warrant Stockholder Approval, and see the section entitled “Warrant Stockholder Approval” on page 56 for additional details regarding the Warrant Stockholder Approval.

We are also offering to each purchaser of Units that would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the Company’s outstanding common stock (or, at the election of the purchaser, 9.99% of the Company’s outstanding common stock) immediately following the consummation of this offering, the opportunity to purchase Units consisting of (i) one pre-funded warrant in lieu of one share of common stock (each, a “Pre-Funded Warrant”), (ii) one Series A Warrant, and (iii) one Series B Warrant. Subject to limited exceptions, a holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if it would result in the holder, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the Company’s outstanding common stock (or, at the election of the holder, 9.99% of the Company’s outstanding shares of common stock) immediately after giving effect to such exercise. Each Pre-Funded Warrant will be exercisable for one share of common stock at an exercise price equal to $0.0001 per share and may be exercised on a cashless basis. The purchase price of each Unit that includes a Pre-Funded Warrant will be equal to the price per Unit that includes one share of common stock, minus $0.0001. The Pre-Funded Warrants will be immediately exerc